Ross, H. J., Kozono, D. E., Urbanic, J. J., Williams, T. M., Dufrane, C., Bara, I., … Stinchcombe, T. (2018). Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. In Journal of Clinical Oncology (Vol. 36, pp. TPS8585–TPS8585). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585

Ross, Helen J., David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, et al. “Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.” In Journal of Clinical Oncology, 36:TPS8585–TPS8585. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585.

Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, et al. Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS8585–TPS8585.

Ross, Helen J., et al. “Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS8585–TPS8585. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps8585.

Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, Gandhi M, Schulze K, Brockman JM, Wang XF, Vokes EE, Stinchcombe T. Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS8585–TPS8585.